Renaissance Technologies LLC Buys Shares of 263,153 CVS Health Corporation $CVS

Renaissance Technologies LLC acquired a new stake in CVS Health Corporation (NYSE:CVS) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 263,153 shares of the pharmacy operator’s stock, valued at approximately $18,900,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Bollard Group LLC grew its holdings in shares of CVS Health by 0.9% during the 1st quarter. Bollard Group LLC now owns 17,653 shares of the pharmacy operator’s stock worth $1,268,000 after purchasing an additional 157 shares during the period. Gabelli Funds LLC raised its holdings in CVS Health by 1.2% in the 1st quarter. Gabelli Funds LLC now owns 259,700 shares of the pharmacy operator’s stock valued at $18,652,000 after buying an additional 3,000 shares during the period. Modern Wealth Management LLC lifted its position in CVS Health by 5.5% in the first quarter. Modern Wealth Management LLC now owns 5,030 shares of the pharmacy operator’s stock valued at $365,000 after buying an additional 260 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in CVS Health by 44.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator’s stock worth $446,703,000 after buying an additional 1,899,932 shares during the period. Finally, Dickmeyer Boyce Financial Management Inc. acquired a new stake in shares of CVS Health during the first quarter valued at about $371,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts expect CVS Health’s upcoming results to show earnings growth, supported by favorable estimates and recent positive estimate revisions. The outlook reinforces expectations that the company can continue its earnings recovery after reporting quarterly EPS and revenue above consensus in its latest report. CVS Health Earnings Expected to Grow
• Positive Sentiment: UnitedHealth’s second-quarter results—featuring improved margins, a lower medical cost ratio and raised earnings guidance—provide a constructive read-through for managed-care companies including CVS Health, suggesting industry cost pressures may be easing. UnitedHealth Turnaround Signal
• Positive Sentiment: CVS received the overall winner award and four gold awards at the 2026 US Customer Experience Awards, including recognition for AI innovation and consumer-centric culture. The recognition supports management’s efforts to improve customer engagement and digital operations, though it has limited immediate earnings impact. CVS Customer Experience Awards
• Positive Sentiment: CVS expanded its pharmacy offering to include common prescription medications for dogs and cats across approximately 9,000 stores, creating a potential new convenience and prescription-volume opportunity. Pet Medications Available at CVS Pharmacy
• Neutral Sentiment: Health100 earned accreditation for consumer data privacy and security, while CVS settled-related litigation involving X and the World Federation of Advertisers. Both developments may reduce reputational or compliance concerns but are unlikely to materially affect near-term earnings. Health100 Accreditation
• Negative Sentiment: Reports that the Trump administration may discontinue subsidies that help hold down Medicare Part D premiums in 2027 are weighing on health-insurance stocks. The change could increase pricing pressure, membership risk and medical-cost uncertainty for CVS’s Aetna business. Medicare Subsidy Report

Wall Street Analyst Weigh In

CVS has been the topic of several recent analyst reports. TD Cowen upped their price objective on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Weiss Ratings raised CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, July 20th. Truist Financial raised their price target on CVS Health from $108.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. JPMorgan Chase & Co. boosted their price objective on CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and an average price target of $105.67.

Insider Activity at CVS Health

In related news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by corporate insiders.

CVS Health Stock Performance

Shares of CVS stock opened at $105.21 on Friday. The firm has a 50 day moving average of $101.22 and a two-hundred day moving average of $86.91. The stock has a market capitalization of $134.24 billion, a PE ratio of 46.35, a P/E/G ratio of 1.03 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 52 week low of $61.19 and a 52 week high of $110.68.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts predict that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio is presently 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.